RESUMEN
OBJECTIVES: To examine adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases (RMD) who relapse upon tapering of low glucocorticoid dose, despite concomitant treatment with disease-modifying anti-rheumatic drugs (DMARDs). METHODS: A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7.5 mg daily), while being on stable concomitant treatment with methotrexate, leflunomide, hydroxychloroquine, azathioprine, mycophenolate, tofacitinib, belimumab, anti-TNF, anti-IL-6 or anti-IL-1 regimens (n=14; 3; 9; 1; 2; 1; 1; 5; 2; 1, respectively). Sex-matched apparently healthy individuals (n=45) served as controls. RESULTS: Baseline cortisol levels and time-integrated cortisol response to tetracosactide were lower in patients than controls (12.01±4.47 vs. 15.63±4.16 mcg/dl, p=0.001, and 1050±286 vs. 1284±182, p<0.001, respectively). No significant associations were observed between the cortisol response to tetracosactide and age, duration of disease or glucocorticoid treatment. An abnormal Synacthen test, indicative of adrenal insufficiency, presumably secondary to chronic glucocorticoid administration, was noted in 5/25 patients. The remaining 20 patients (80%) had normal Synacthen test demonstrating, however, lower cortisol response than controls, independently of age (ß-coefficient=-0.373, p=0.033). CONCLUSIONS: Patients with RMD in remission under DMARDs who relapse upon concomitant low glucocorticoid dose tapering should be tested for iatrogenic adrenal insufficiency. Whether a marginally normal Synacthen test should discourage further attempts to withdraw glucocorticoid treatment in these patients warrants further investigation.
Asunto(s)
Corteza Suprarrenal , Insuficiencia Suprarrenal , Antirreumáticos , Artritis Reumatoide , Corticoesteroides/uso terapéutico , Insuficiencia Suprarrenal/inducido químicamente , Insuficiencia Suprarrenal/diagnóstico , Insuficiencia Suprarrenal/tratamiento farmacológico , Antirreumáticos/efectos adversos , Artritis Reumatoide/tratamiento farmacológico , Azatioprina/uso terapéutico , Enfermedad Crónica , Cosintropina/uso terapéutico , Glucocorticoides/efectos adversos , Humanos , Hidrocortisona/uso terapéutico , Hidroxicloroquina/uso terapéutico , Leflunamida/uso terapéutico , Metotrexato/uso terapéutico , Prednisolona/uso terapéutico , Recurrencia , Inhibidores del Factor de Necrosis TumoralRESUMEN
OBJECTIVE: Sounds in everyday environments tend to follow one another as events unfold over time. The tacit knowledge of contextual relationships among environmental sounds can influence their perception. We examined the effect of semantic context on the identification of sequences of environmental sounds by adults of varying age and hearing abilities, with an aim to develop a nonspeech test of auditory cognition. METHOD: The familiar environmental sound test (FEST) consisted of 25 individual sounds arranged into ten five-sound sequences: five contextually coherent and five incoherent. After hearing each sequence, listeners identified each sound and arranged them in the presentation order. FEST was administered to young normal-hearing, middle-to-older normal-hearing, and middle-to-older hearing-impaired adults (Experiment 1), and to postlingual cochlear-implant users and young normal-hearing adults tested through vocoder-simulated implants (Experiment 2). RESULTS: FEST scores revealed a strong positive effect of semantic context in all listener groups, with young normal-hearing listeners outperforming other groups. FEST scores also correlated with other measures of cognitive ability, and for CI users, with the intelligibility of speech-in-noise. CONCLUSIONS: Being sensitive to semantic context effects, FEST can serve as a nonspeech test of auditory cognition for diverse listener populations to assess and potentially improve everyday listening skills.
Asunto(s)
Percepción Auditiva/fisiología , Ambiente , Pérdida Auditiva/fisiopatología , Audición/fisiología , Semántica , Localización de Sonidos , Percepción del Habla , Estimulación Acústica , Adolescente , Adulto , Anciano , Estudios de Casos y Controles , Cognición/fisiología , Femenino , Pérdida Auditiva/rehabilitación , Pruebas Auditivas/métodos , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Our aim was to assess liver iron content, in thalassaemic patients, by using three different MR protocols and compare their data. Ninety-four thalassaemic patients (44 M and 50 F, mean age 25.82 +/- 8.3 yrs), were enrolled in the study. In each patient, three measurements of the liver iron content were performed, with the use of a single imager, equipped with a 1.5 Tesla magnet. Liver R2* was measured on gradient-echo sequence. Calculation of MR-HIC values was based on an algorithm using liver to muscle (L/M) ratios in five axial gradient-echo sequences. Finally, determination of liver R2 employed a 16-echo, spin-echo pulse sequence. Additionally, myocardial R2* value was determined for each patient. Results showed that all three magnetic resonance imaging (MRI) methods were highly correlated to each other and significantly correlated to serum ferritin concentrations. Liver R2 method showed an increased sensitivity in detecting liver iron contents in the upper range. No correlation occurred between each liver MRI parameter and myocardial R2* values. Finally, we managed to provide formulae for equating values obtaining with any of these three MRI methods.
Asunto(s)
Hierro/análisis , Hígado/química , Imagen por Resonancia Magnética/métodos , Talasemia/metabolismo , Adolescente , Adulto , Algoritmos , Femenino , Humanos , Imagen por Resonancia Magnética/normas , Masculino , Miocardio/metabolismo , Adulto JovenRESUMEN
The aim of this study was to compare the effect of different long-term chelation regimens on heart and liver iron stores with the use of T2* magnetic resonance imaging (MRI) in patients with transfusion-dependent beta-thalassemia major. Sixty-four patients (28 men, 36 women; mean age, 26.49 +/- 5.8 years) were enrolled in the study. The 3 groups were based on the chelation therapy received. The first group (19 patients) received deferiprone (DFP) (75 mg/kg per day orally), the second group (23 patients) received deferoxamine (DFO) (30-50 mg/kg per day subcutaneously at least 5 times/week), and the third group (22 patients) received a combination of DFO (30-50 mg/kg per day, 2-3 days/week) and DFP (75 mg/kg per day, 7 days/week). MRI scans were acquired with an imager equipped with a 1.5 T magnet, and the data included myocardial and hepatic iron measurements obtained by means of T2*, and ventricular volumes and ejection fractions obtained with standard cardiovascular MRI techniques. The results revealed that the DFP and the combined groups had significantly less myocardial iron than the DFO group (mean myocardial T2*, 35.77 +/- 18.3 milliseconds and 38.05 +/- 15.3 milliseconds versus 23.77 +/- 13 milliseconds [P = .02, and P = .001], respectively). On the contrary, the DFP group had a significantly higher hepatic iron content than the DFO and combined groups (mean hepatic T2*, 3.29 +/- 2.5 milliseconds versus 8.16 +/- 8.4 milliseconds and 11.3 +/- 10.9 milliseconds [P = .014, and P = .003], respectively). No correlation was observed between myocardial T2* and hepatic T2* values (r = -0.043; P = .37). Myocardial T2* values were inversely correlated with age (r = -0.249; P = .024) and positively correlated with both left and right ventricular ejection fractions (r = 0.33 [P = .004], and r = 0.279 [P = .014], respectively). Finally, liver T2* was strongly and inversely correlated with serum ferritin concentration (r = -0.465; P = .001). In conclusion, combined chelation therapy seems to sum the beneficial effects of DFO and DFP with respect to hepatic and myocardial iron. Because myocardial iron is not related to measurements of serum ferritin or hepatic T2*, important decisions on clinical management relating to cardiac risk should not rely on these conventional parameters. Thus, the use of MRI for assessing myocardial iron should be adopted in the routine clinical management of patients with beta-thalassemia major.
Asunto(s)
Deferoxamina/administración & dosificación , Hierro/metabolismo , Hígado/metabolismo , Imagen por Resonancia Magnética , Miocardio/metabolismo , Piridonas/administración & dosificación , Sideróforos/administración & dosificación , Talasemia beta/metabolismo , Adolescente , Adulto , Deferiprona , Femenino , Ferritinas , Ventrículos Cardíacos , Humanos , Hígado/diagnóstico por imagen , Estudios Longitudinales , Masculino , Monitoreo Fisiológico/métodos , Tamaño de los Órganos/efectos de los fármacos , Radiografía , Factores de Tiempo , Talasemia beta/diagnóstico por imagen , Talasemia beta/tratamiento farmacológicoRESUMEN
We report a rare case of coexistent pheochromocytoma and abdominal aortic aneurysm (AAA). The patient was a 72-year-old man who presented to the Emergency Department with severe dyspnea and hypertension. Physical examination revealed a pulsatile mass in his abdomen. A computed tomography scan, done after pharmacological treatment of his symptoms, showed a thoraco-AAA and a left adrenal mass. His urinary vanylmandelic acid and metanephrine levels were found to be elevated, strongly indicative of a diagnosis of pheochromocytoma. We gave the patient phenoxybenzamine, an alpha-blocker, preoperatively, then resected the adrenal mass and repaired the AAA. The patient had an uneventful recovery. The diagnosis of pheochromocytoma was confirmed histologically. To our knowledge, this is the first reported case of elective resection of both these lesions.